In December 2019, the Antibacterial Resistance Leadership Group (ARLG) was awarded funding for another seven-year cycle to support a clinical research network on antibacterial resistance. ARLG 2.0 has three overarching research priorities: (1) infections caused by antibiotic resistant (AR) Gram-negative bacteria; (2) infections caused by AR Gram-positive bacteria, and (3) diagnostic tests to optimize use of antibiotics. To support the next generation of AR researchers, the ARLG offers three mentoring opportunities: the ARLG Fellowship, Early Stage Investigator Seed Grants, and the Trialists in Training Program. The purpose of this article is to update the scientific community on the progress made in the original funding period and to encourage submission of clinical research that addresses one or more of the research priority areas of ARLG 2.0.
Reference Type
Journal Article
Periodical Full
Clinical infectious diseases
Publication Year
2021
Publication Date
Feb 15,
Place of Publication
United States
ISSN/ISBN
1058-4838
Document Object Index
10.1093/cid/ciab141
URL
https://www.ncbi.nlm.nih.gov/pubmed/33588438
PMID
33588438